Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.
复制标题
特拉万星 (TD-6424) 的体外活性比较，这是一种快速杀菌、浓度依赖性抗感染药，具有多种针对革兰氏阳性菌的作用机制。
DOI：
--
复制
发表时间：
2004
影响因子：
5.2
通讯作者：
K. Kaniga
中科院分区：
文献类型：
--
作者：
A. King;I. Phillips;K. Kaniga
目的
我们通过NCCLS/EUCAST和BSAC方法，比较了特拉万星与万古霉素、替考拉宁、利奈唑胺、奎奴普汀/达福普汀、阿替沙星和氨苄西林、青霉素或苯唑西林（如适用）的体外活性。
方法
本研究中纳入的微生物（n = 401）是来自St托马斯医院的患者分离株，并选择包括临床重要革兰氏阳性需氧菌的代表。根据NCCLS/EUCAST指导原则，通过琼脂稀释法在Mueller-Hinton琼脂上进行敏感性试验，并与根据BSAC指导原则的Iso-Sensitest琼脂进行比较。
结果
特拉万星对所有测试的革兰氏阳性物种都有活性，并且研究中包括的近90%的分离株具有特拉万星MIC </= 1 mg/L。万古霉素MIC> 64 mg/L的万古霉素耐药肠球菌和乳酸杆菌分离株的特拉万星MIC范围分别为0.5 - 8和2 - 16 mg/L。没有证据表明与其他对照药物存在交叉耐药性。两种药敏试验方法的特拉万星结果大多相同或在一个加倍稀释内。
结论
特拉万星的敏感性折点尚未确定，但特拉万星似乎具有优于其他测试的糖肽的上级效力，并且基于重量比显示出与其他测试的药剂相当或更好的活性。
OBJECTIVE
We compared the in vitro activity of telavancin with that of vancomycin, teicoplanin, linezolid, quinupristin/dalfopristin, moxifloxacin and ampicillin, penicillin or oxacillin as appropriate, by the NCCLS/EUCAST and BSAC methods.
METHODS
The organisms (n = 401) included in the study were patient isolates from St Thomas' Hospital and were selected to include representatives of the clinically important Gram-positive aerobic species. Susceptibility testing was performed by agar dilution methods on Mueller-Hinton agar according to the NCCLS/EUCAST guidelines, in comparison with Iso-Sensitest agar according to the BSAC guidelines.
RESULTS
Telavancin was active against all the Gram-positive species tested and nearly 90% of isolates included in the study had telavancin MICs </= 1 mg/L. Vancomycin-resistant enterococci and lactobacilli isolates with vancomycin MICs > 64 mg/L had telavancin MIC ranges of 0.5-8 and 2-16 mg/L, respectively. There was no evidence of cross-resistance with other comparator drugs. The results for telavancin for the two susceptibility testing methods were mostly either the same or within one doubling dilution.
CONCLUSION
The susceptibility breakpoints for telavancin have yet to be established, but it would appear that telavancin has superior potency to the other tested glycopeptides, and on a weight-for-weight basis displays activity that is comparable to, or better than, that of the other agents tested.